Merck KGaA has prepared and tested new antibody-drug conjugates (ADCs) comprising monoclonal antibodies targeting sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi-2b) linked to exatecan through a β-glucuronidase cleavable linker. They are described as potentially useful for the treatment of ovarian and non-small-cell lung cancer.
Shanghai Apeiron Biotechnology Co. Ltd. has reported selenium-containing heterocyclic compounds acting as DNA polymerase theta (POLθ, POLQ) inhibitors potentially useful for the treatment of cancer.
AC Immune SA has synthesized thiazolo[5,4-c]pyridine-4(5H)-one derivatives acting as TAR DNA-binding protein 43 (TARDBP; TDP-43) aggregation ligands reported to be useful for the diagnosis of amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, limbic-predominant age-related TDP-43 encephalopathy and traumatic encephalopathy.
University of Basel and NXI Therapeutics AG have jointly patented compounds targeting bromodomain-containing protein 3 (BRD3; RING3-like protein) to inhibit expression of coronin-1. They are described as potentially useful for the treatment of transplant rejection, autoimmune diseases, inflammation, infections and lymphoproliferative disorders.
In a recent publication in iScience, researchers from Peking University First Hospital investigated the therapeutic potential of SLC7A11 CAR T therapy for solid tumors, particularly colorectal and pancreatic cancers.
Sickle cell disease (SCD) is a genetic disorder caused by a single point mutation in the β-globin gene, leading to the production of abnormal hemoglobin. Patients with SCD lacking a compatible donor for allogeneic hematopoietic stem/progenitor cell transplantation can benefit from gene therapy approaches.
Ventus Therapeutics Inc. has entered into a multi-year collaboration with Genentech Inc., a member of the Roche Group, to discover and optimize novel small-molecule candidates for challenging targets in major disease areas using Ventus’ Resolve drug discovery platform.
Smartbax GmbH has announced the successful first closing of its €4.7 million (US$5.4 million) pre-series A financing round to support development of its next-generation antibiotics against multidrug-resistant (MDR) bacteria. A second closing of the round remains open to investors.
Researchers at University of South China and collaborators have generated numerous carbamate-based N-benzoyl tryptamine derivatives for Alzheimer’s disease.
RSS
